4.6 Review

Opioid Use in Fibromyalgia: A Cautionary Tale

Journal

MAYO CLINIC PROCEEDINGS
Volume 91, Issue 5, Pages 640-648

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.mayocp.2016.02.002

Keywords

-

Funding

  1. Pfizer
  2. Eli Lilly
  3. Forest Laboratories
  4. Johnson Johnson
  5. Purdue Pharma
  6. Nuvo
  7. Cerephex
  8. Tonix
  9. Iroko
  10. Takaeda
  11. IMC
  12. Zynerba
  13. Samumed

Ask authors/readers for more resources

Multiple pharmacotherapies are available for the treatment of fibromyalgia (FM), including opioid analgesics. We postulate that the mechanism of action of traditional opioids predicts their lack of efficacy in FM. Literature searches of the MEDLINE and Cochrane Library databases were conducted using the search term opioid AND fibromyalgia to identify relevant articles, with no date limitations set. Citation lists in returned articles and personal archives of references were also examined for additional relevant items, and articles were selected based on the expert opinions of the authors. We found no evidence from clinical trials that opioids are effective for the treatment of FM. Observational studies have found that patients with FM receiving opioids have poorer outcomes than patients receiving nonopioids, and FM guidelines recommend against the use of opioid analgesics. Despite this, and despite the availability of alternative Food and Drug Administration-approved pharmacotherapies and the efficacy of nonpharmacologic therapies, opioids are commonly used in the treatment of FM. Factors associated with opioid use include female sex; geographic variation; psychological factors; a history of opioid use, misuse, or abuse; and patient or physician preference. The long-term use of opioid analgesics is of particular concern in the United States given the ongoing public health emergency relating to excess prescription opioid consumption. The continued use of opioids to treat FM despite a proven lack of efficacy, lack of support from treatment guidelines, and the availability of approved pharmacotherapy options provides a cautionary tale for their use in other chronic pain conditions. (C) 2016 Mayo Foundation for Medical Education and Research

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available